A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome

Haematologica

Volumn 96, Issue 10, 2011, Pages 1441-1447

  Lee, Je Hwan ^a   Jang, Jun Ho ^b   Park, Jinny ^c   Park, Seonyang ^d   Joo, Young Don ^e   Kim, Yeo Kyeoung ^f   Kim, Hoon Gu ^g   Choi, Chul Won ^h   Kim, Sung Hyun ⁱ   Park, Seong Kyu ^j   Park, Eunkyung ^k   Min, Yoo Hong ^l  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Gachon University   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Inje University College of Medicine   (South Korea)

^f Chonnam National University Hwasun Hospital and Medical School   (South Korea)

^g Gyeongsang National University   (South Korea)

^h Korea University College of Medicine   (South Korea)

ⁱ Dong A University College of Medicine   (South Korea)

^j Soonchunhyang University   (South Korea)

^k Chung Ang University College of Medicine   (South Korea)

^l Yonsei University College of Medicine   (South Korea)

more..

Author keywords

Decitabine; MDS; Observational study

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIBIOTIC AGENT;

ABSCESS; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ANTIMICROBIAL THERAPY; ARTICLE; CELLULITIS; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INFECTION; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KOREA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; SEPTICEMIA; SINUSITIS; SOUTH KOREA; THROMBOCYTOPENIA; TONSILLITIS; TUBERCULOSIS; URINARY TRACT INFECTION; VIRUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80053622261     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.046078     Document Type: Article

References (28)

1. Leone G, Teofili L, Voso MT, Lubbert M. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324-41.
2. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-96.
3. Herman JG. Hypermethylation of tumor suppressor genes in cancer. Semin Cancer Biol. 1999;9(5):359-67.
4. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20(1):85-93.
5. Mund C, Hackanson B, Stresemann C, Lubbert M, Lyko F. Characterization of DNA demethylation effects induced by 5- Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. Cancer Res. 2005;65(16):7086-90.
6. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag. 2007;3(5):807-17.
7. Pinto A, Zagonel V. 5-Aza-2'-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia. 1993;7 (Suppl 1):51-60.
8. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5- Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11(1):1-5.
9. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794-803.
10. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5- aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18(5):956-62.
11. Wijermans P, Suciu S, Baila L, Platzbecker U, Giagounidis A, Selleslag D, et al. Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups. Blood. 2008;112(11): Abstract 226.
12. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007; 109(1):52-7.
13. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol. 2009; 27(23):3842-8.
14. Lee JH, Lee KH, Kim DY, Kim SH, Lim SN, Kim SD, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res. 2011;35(4):499-503.
15. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.
16. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983;1(11):710-9.
17. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables. J Clin Oncol. 2008;26(24): 3913-5.
18. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223-32.
19. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27(11):1850-6.
20. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24(24):3895-903.
21. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079-88.
22. Muller-Berndorff H, Haas PS, Kunzmann R, Schulte-Monting J, Lubbert M. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: Results of a single-center analysis. Ann Hematol. 2006;85(8):502-13.
23. Navarro I, Ruiz MA, Cabello A, Collado R, Ferrer R, Hueso J, et al. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients. Leuk Res. 2006;30(8):971-7.
24. Lee JH, Shin YR, Lee JS, Kim WK, Chi HS, Park CJ, et al. Application of different prognostic scoring systems and comparison of the FAB and WHO classifications in Korean patients with myelodysplastic syndrome. Leukemia. 2003;17(2):305-13.
25. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005; 106(8):2633-40.
26. Wang XQ, Ryder J, Gross SA, Lin G, Irons RD. Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. Int J Hematol. 2009;90(3):361-9.
27. Geils GF. Clnical experience of decitabine in elderly patients with myelodysplastic syndrome (MDS). Blood. 2009;114(22): Abstract 2792.
28. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96(12):3671-4.